Previous Close | 43.97 |
Open | 43.63 |
Bid | 0.00 x 1300 |
Ask | 0.00 x 4000 |
Day's Range | 43.50 - 44.46 |
52 Week Range | 41.45 - 56.32 |
Volume | |
Avg. Volume | 21,887,870 |
Market Cap | 248.894B |
Beta (5Y Monthly) | 0.63 |
PE Ratio (TTM) | 8.11 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 1.64 (3.73%) |
Ex-Dividend Date | Jan 26, 2023 |
1y Target Est | N/A |
NEW YORK, January 31, 2023--Pfizer Inc. (NYSE: PFE) reported exceptional financial results for fourth-quarter and full-year 2022 and provided 2023 financial guidance(4).
DAVOS, Switzerland, January 17, 2023--Pfizer Inc. (NYSE: PFE) today announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccines for which it has global rights on a not-for-profit basis to enable greater health for 1.2 billion people living in 45 lower-income countries.
NEW YORK, January 06, 2023--Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review a supplemental Biologics License Application (sBLA) for its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes contained in the vaccine in infants and children 6 weeks through 17 years of age, and for the prevention of ot